Perspective Therapeutics (CATX) Asset Utilization Ratio (2011 - 2023)
Perspective Therapeutics (CATX) reported Asset Utilization Ratio of 0.01 for Q4 2023, down 92.73% sequentially from 0.11 in Q3 2023.
Perspective Therapeutics (CATX) Asset Utilization Ratio (2011 - 2023) Analysis & Trends
Perspective Therapeutics (CATX) has 12 years of Asset Utilization Ratio data on file, last reported at 0.01 in Q4 2023.
- For the quarter ending Q4 2023, Asset Utilization Ratio changed N/A year-over-year to 0.01; the trailing twelve-month figure through Dec 2023 stood at 0.01 (changed N/A YoY), and the FY2023 full-year result was 0.02, changed N/A from the prior year.
- Asset Utilization Ratio fell to 0.01 in Q4 2023, from 0.11 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 1.17 in Q3 2020 to a low of 0.01 in Q4 2023.
- A 5-year average of 0.47 and a median of 0.22 in 2021 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio slumped 87.38% in 2021 and soared 95.65% in 2022, its largest moves.
- Tracing CATX's Asset Utilization Ratio over 5 years: stood at 0.88 in 2019, then declined by 4.21% to 0.84 in 2020, then slumped by 81.31% to 0.16 in 2021, then jumped by 83.03% to 0.29 in 2022, then tumbled by 97.18% to 0.01 in 2023.
- Business Quant data shows CATX's Asset Utilization Ratio at 0.01 in Q4 2023, 0.11 in Q3 2023, and 0.13 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 0.46 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 0.54 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 0.39 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 0.47 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 0.47 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 0.74 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.65 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 0.57 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.11 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | 0.19 |
| Sep 30, 2022 | 0.29 |
| Jun 30, 2022 | 0.21 |
| Mar 31, 2022 | 0.16 |
| Dec 31, 2021 | 0.16 |
| Sep 30, 2021 | 0.15 |
| Jun 30, 2021 | 0.14 |
| Mar 31, 2021 | 0.22 |
| Dec 31, 2020 | 0.84 |
| Sep 30, 2020 | 1.17 |
| Jun 30, 2020 | 1.10 |
| Mar 31, 2020 | 1.04 |
| Dec 31, 2019 | 0.88 |
| Sep 30, 2019 | 0.83 |
| Jun 30, 2019 | 0.73 |
| Mar 31, 2019 | 0.62 |
| Dec 31, 2018 | 0.53 |